Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 21 | 2024 | 688 | 6.180 |
Why?
|
| Adenocarcinoma | 8 | 2023 | 1003 | 2.540 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2022 | 155 | 1.520 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 558 | 1.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 303 | 0.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1199 | 0.840 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2014 | 642 | 0.830 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 326 | 0.810 |
Why?
|
| Barrett Esophagus | 3 | 2014 | 334 | 0.760 |
Why?
|
| Ileitis | 1 | 2020 | 10 | 0.710 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2020 | 8 | 0.710 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 404 | 0.660 |
Why?
|
| Diabetes Mellitus | 3 | 2024 | 840 | 0.660 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 98 | 0.630 |
Why?
|
| Veterans | 2 | 2023 | 1707 | 0.600 |
Why?
|
| Colonic Polyps | 1 | 2019 | 78 | 0.580 |
Why?
|
| Risk Factors | 13 | 2024 | 9673 | 0.570 |
Why?
|
| Crohn Disease | 1 | 2020 | 281 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2018 | 710 | 0.530 |
Why?
|
| Aspirin | 1 | 2017 | 220 | 0.530 |
Why?
|
| Proportional Hazards Models | 6 | 2023 | 1284 | 0.500 |
Why?
|
| Coffee | 1 | 2015 | 23 | 0.490 |
Why?
|
| Caffeine | 1 | 2015 | 69 | 0.480 |
Why?
|
| Aged | 18 | 2024 | 18463 | 0.470 |
Why?
|
| Gastric Balloon | 1 | 2014 | 2 | 0.460 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2014 | 16 | 0.460 |
Why?
|
| Air | 1 | 2014 | 26 | 0.460 |
Why?
|
| Mesenteric Ischemia | 1 | 2014 | 11 | 0.460 |
Why?
|
| Humans | 36 | 2024 | 121732 | 0.450 |
Why?
|
| Portal Vein | 1 | 2014 | 89 | 0.440 |
Why?
|
| United States | 8 | 2023 | 10415 | 0.440 |
Why?
|
| Middle Aged | 19 | 2024 | 25390 | 0.420 |
Why?
|
| Device Removal | 1 | 2014 | 219 | 0.400 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2012 | 62 | 0.390 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 93 | 0.390 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 319 | 0.370 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1057 | 0.340 |
Why?
|
| Feeding Behavior | 1 | 2015 | 676 | 0.330 |
Why?
|
| Body Composition | 2 | 2023 | 472 | 0.320 |
Why?
|
| Prevalence | 2 | 2019 | 2370 | 0.320 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 822 | 0.310 |
Why?
|
| Incidence | 4 | 2020 | 2985 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 948 | 0.290 |
Why?
|
| Endoscopy, Digestive System | 3 | 2019 | 153 | 0.290 |
Why?
|
| Male | 19 | 2020 | 59115 | 0.270 |
Why?
|
| Mass Screening | 2 | 2022 | 776 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3223 | 0.250 |
Why?
|
| Female | 16 | 2020 | 64469 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2021 | 5898 | 0.220 |
Why?
|
| Gastroenterologists | 1 | 2023 | 11 | 0.220 |
Why?
|
| Risk Assessment | 3 | 2017 | 3219 | 0.200 |
Why?
|
| Cyst Fluid | 1 | 2021 | 5 | 0.200 |
Why?
|
| Survival Analysis | 4 | 2019 | 1460 | 0.190 |
Why?
|
| Adult | 9 | 2020 | 28621 | 0.190 |
Why?
|
| International Classification of Diseases | 1 | 2022 | 88 | 0.190 |
Why?
|
| Pancreatic Cyst | 1 | 2021 | 30 | 0.190 |
Why?
|
| Pancreas | 1 | 2022 | 213 | 0.190 |
Why?
|
| Logistic Models | 2 | 2023 | 1756 | 0.180 |
Why?
|
| Adipose Tissue | 2 | 2023 | 446 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 1978 | 0.180 |
Why?
|
| Survival Rate | 3 | 2020 | 1983 | 0.180 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 287 | 0.180 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 49 | 0.170 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 312 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 234 | 0.170 |
Why?
|
| Duodenal Diseases | 1 | 2019 | 34 | 0.170 |
Why?
|
| Neoplasms | 1 | 2014 | 2749 | 0.160 |
Why?
|
| Jews | 1 | 2019 | 31 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 72 | 0.160 |
Why?
|
| Lymph Nodes | 2 | 2019 | 379 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 196 | 0.160 |
Why?
|
| Syphilis | 1 | 2019 | 95 | 0.160 |
Why?
|
| Penicillins | 1 | 2019 | 154 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2019 | 106 | 0.160 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6100 | 0.160 |
Why?
|
| Leukocytes | 1 | 2019 | 209 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 603 | 0.150 |
Why?
|
| Protective Factors | 1 | 2017 | 82 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2023 | 15610 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2020 | 313 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 252 | 0.150 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 923 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 537 | 0.140 |
Why?
|
| Nurses | 1 | 2017 | 62 | 0.140 |
Why?
|
| Weight Loss | 1 | 2020 | 441 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2017 | 1226 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 157 | 0.140 |
Why?
|
| Health Surveys | 1 | 2017 | 235 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1395 | 0.140 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 59 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 4985 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 730 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2020 | 1456 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3066 | 0.130 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 133 | 0.130 |
Why?
|
| Paris | 1 | 2015 | 10 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2019 | 382 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 559 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2020 | 4632 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 670 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 47 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 4477 | 0.110 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2013 | 21 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 1309 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 1251 | 0.110 |
Why?
|
| Registries | 1 | 2020 | 1351 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2019 | 989 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 141 | 0.100 |
Why?
|
| Smoking | 1 | 2018 | 1027 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 237 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 148 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 370 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2014 | 238 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1115 | 0.100 |
Why?
|
| Dyslipidemias | 1 | 2014 | 227 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 492 | 0.090 |
Why?
|
| Age of Onset | 1 | 2012 | 569 | 0.090 |
Why?
|
| Family | 1 | 2014 | 569 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2789 | 0.080 |
Why?
|
| Time Factors | 1 | 2017 | 5997 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2018 | 134 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3283 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 865 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1515 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 5738 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 78 | 0.060 |
Why?
|
| Cachexia | 1 | 2023 | 49 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 259 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 101 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 864 | 0.050 |
Why?
|
| Muscular Atrophy | 1 | 2023 | 75 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 212 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 726 | 0.050 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 8 | 0.040 |
Why?
|
| Treponema pallidum | 1 | 2019 | 49 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2019 | 118 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 11698 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 743 | 0.040 |
Why?
|
| Telomere | 1 | 2019 | 207 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2024 | 747 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2017 | 51 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 123 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 124 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 92 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 398 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 791 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1242 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1277 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1393 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1710 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1873 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 2013 | 32 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 215 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 1850 | 0.030 |
Why?
|
| Child | 1 | 2012 | 24035 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1674 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1421 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1889 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2059 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2378 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 2486 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 2085 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3432 | 0.010 |
Why?
|